肺肝样腺癌诊治研究进展  

Progress in diagnosis and treatment of hepatoid adenocarcinoma of the lung

作　　者：陈雪芬 韦虹羽 孙起翔 赵华[1] 闫萍[1] 龚臣[1] Chen Xuefen;Wei Hongyu;Sun Qixiang;Zhao Hua;Yan Ping;Gong Chen(Geriatric Respiratory Medicine Department,First Affiliated Hospital of Guangxi Medical University,Nanning 530021,China)

机构地区：[1]广西医科大学第一附属医院老年病学呼吸内科,南宁530021

出　　处：《中华临床医师杂志（电子版）》2024年第1期83-86,共4页Chinese Journal of Clinicians(Electronic Edition)

基　　金：广西壮族自治区卫生健康委员会自筹经费科研课题资助项目(No.Z20210089)。

摘　　要：肺肝样腺癌(HAL)是一种罕见且具有侵袭性的肺癌病理亚型,其组织学特征类似于肝细胞癌,好发于老年男性,其发生可能与胚胎发育过程中原始潜能干细胞发育异常相关,诊断及鉴别诊断需依靠影像学等排除其他部位肝样腺癌并结合病灶形态学及免疫组化进行综合判断,血清AFP水平与疾病活动相关,但AFP与预后的关系仍有待更多数据支撑,HAL患者预后较非小细胞肺癌差,目前尚无统一治疗指南,多推荐参考肺腺癌方案,本文旨在就HAL的诊治进展进行综述,以增进对这种独特实体瘤的理解,以提高临床上对该病的诊治水平。Hepatoid adenocarcinoma of the lung(HAL)is a rare and aggressive pathological subtype of lung cancer.With histological characteristics resembling those of hepatocellular carcinoma,HAL predominantly affects elderly men.The development of HAL may be associated with abnormal development of primitive pluripotent stem cells during embryonic development.Its diagnosis and differential diagnosis rely on the exclusion of hepatoid adenocarcinoma in other locations through imaging studies,as well as comprehensive evaluation based on lesion morphology and immunohistochemistry.Serum alpha-fetoprotein(AFP)levels are associated with disease activity,but the relationship between AFP and prognosis requires more supporting data.HAL patients have a worse prognosis compared to non-small cell lung cancer patients,and there are currently no unified treatment guidelines.Treatment recommendations often refer to those for lung adenocarcinoma.This article aims to provide a comprehensive review of the progress in the diagnosis and treatment of HAL,in order to enhance understanding of this unique solid tumor and improve its clinical management.

关 键 词：肝样腺癌 肺肿瘤 临床病理学 发病机制 

分 类 号：R735.7[医药卫生—肿瘤]